Abstract
New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 192-195 |
| Number of pages | 4 |
| Journal | Cancer Treatment Communications |
| Volume | 4 |
| DOIs | |
| State | Published - Jan 1 2015 |
| Externally published | Yes |
Fingerprint
Keywords
- Castrate-resistant
- Everolimus
- Pasireotide
- Phase II
- Prostate cancer
ASJC Scopus subject areas
- Oncology
Cite this
An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients. / Lin, Jianqing; Deng, Aileen; Hoffman-Censits, Jean; Gibney, Geoffrey; Hyslop, Terry; Miller, Brooke; Kilpatrick, Deborah; Jabbour, Serge; Kevin Kelly, William.
In: Cancer Treatment Communications, Vol. 4, 01.01.2015, p. 192-195.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients
AU - Lin, Jianqing
AU - Deng, Aileen
AU - Hoffman-Censits, Jean
AU - Gibney, Geoffrey
AU - Hyslop, Terry
AU - Miller, Brooke
AU - Kilpatrick, Deborah
AU - Jabbour, Serge
AU - Kevin Kelly, William
PY - 2015/1/1
Y1 - 2015/1/1
N2 - New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.
AB - New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.
KW - Castrate-resistant
KW - Everolimus
KW - Pasireotide
KW - Phase II
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=84947923941&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947923941&partnerID=8YFLogxK
U2 - 10.1016/j.ctrc.2015.11.003
DO - 10.1016/j.ctrc.2015.11.003
M3 - Article
AN - SCOPUS:84947923941
VL - 4
SP - 192
EP - 195
JO - Cancer Treatment and Research Communications
JF - Cancer Treatment and Research Communications
SN - 2213-0896
ER -